Rafael Amado: Yes, I’ll take that question. Thanks for this insightful question. I think the most important thing is to understand that with primary endpoint with both statistically and clinically meaningful results on the primary endpoint, and in any study, that’s really what matters. It is a randomized trial and population has been studied is the post-platinum population. So prior PD-1 is not an exclusion criteria. And the studies randomized so we see and strive to stratify as well and factors are supposed to mitigate professional imbalances. So the important point, I think, is that regardless of the makeup of the PD-1 subgroup, there was a statistically significant and clinically meaningful difference in overall survival in the overall population and in the PD-1 subgroup was a trend in the docetaxel group.
So the details of the patient characteristics and prior treatment history will be shared future data presentation and the release, its owned by . So rather than speculating on subgroups, I think it’s best to just wait for the full analysis. Also data set to interpret their results. But we should be cautious about subgroup analysis and really focus on the primary analysis, which has results that were pretty exciting as reported by .
Yang Huang: Okay, got it. Yes, my second question is, have you got more commercial preparation as to we understand the kind of rare disease in China as well. And so can company let us know — has company has started to try to identify some MG patient, just to prepare for the launch of the drug? And if so, can you let us know, kind of how many mg patients you have identified so far?
Billy Cho: Yes, hey, Yang, I’ll take this one. So, first of all, the addressable patient pool is quite large for MG. We’re talking about a prevalence of about 200,000. And we strongly believe that will become a very important treatment option for these patients. It’s early days, but we have started to build awareness ahead of the anticipated approval launch, as you know. We’ve launched a program in a part of China, where patients can potentially get access, it was really more for strategic purposes, given travel restrictions up until recently, but it really allowed us to engage with not only the physician, but patients and get some feedback responses, and it’s quite encouraged by what we see. And no surprise, right, given what’s been happening outside of China, I believe argenx just reported, a pretty, pretty strong first year sales and engagement and whatever metrics that you follow on the commercial side, so I think that provides a nice read through for the potential and opportunity in China.
Yang Huang: Okay, great. Thank you.
Operator: Thank you for your question. There are no further questions at the moment. I will hand back for closing remarks.
Samantha Du: Thank you, operator. I want to thank everyone for taking the time to join us on the call today. We appreciate your support. We look forward to updating you again after the first quarter of 2023. Operator, you may now disconnect the call.
